Pharmafile Logo
Pharmafocus logo
Advanced Search

UK

Showing 15 posts of 472 posts found.

five-clear-glass-vial-bottles

Scotland approves targetted combination therapy for advanced melanoma

February 11, 2020
Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma

The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …

News
assorted-condoms

Funding cuts and government inaction has led to soaring STI rates in Britain, new study finds

February 5, 2020
Research and Development AIDS, HIV, STDs, STIs, UK, sexual health

The UK faces a new Sexually Transmitted Infection (STI) diagnoses every 70 seconds, according to a new report that outlines …

News
pharmafocus_janfeb_2020_cover

Read the January/February 2020 edition of Pharmafocus online now!

January 30, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, US, brexit, coronavirus, opioid crisis, pharma

Pharmafocus returns for the New Year with its January/February issue, and things have certainly changed since we left. Brexit got …

News

NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

January 27, 2020
Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …

News

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

News
lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

News

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …

News
uk

Scotland leading the UK in life science start-up growth, report reveals

November 20, 2019
Research and Development, Sales and Marketing BioCity, UK, biotech, pharma

A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …

News
shutter

UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships

October 28, 2019
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, pharma, research

The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of …

News
brexit-hintergrund_web

“No deal” Brexit and life sciences: What happens?

October 21, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …

Feature
merckwindow_web

Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer

October 7, 2019
Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …

News

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019
Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …

News
470px-blank_ireland

Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority

September 5, 2019
Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma

Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …

News

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019
Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …

News
shutterstock_2

University of Limerick’s Pharmaceutical Manufacturing Technology Centre to expand operations with €5m funding injection

September 3, 2019
Manufacturing and Production Ireland, UK, pharma

The Pharmaceutical Manufacturing Technology Centre (PMTC) at the University of Limerick’s Bernal Institute in Ireland has secured €5 million ($5.5 …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026